Hamburg - 24 July 2014: Evotec AG today announced the publication of its fifth DDup edition. It focuses on antibiotic drug discovery and Evotec’s new capabilities and expertise in anti-infectives. DDup 5 highlights Evotec’s recently established alliance with Harvard aimed at discovering and developing novel anti-bacterial agents, based on a highly validated target family involved in bacterial cell wall biosynthesis, and the recent acquisition of Euprotec. This edition also provides insights into Evotec’s capabilities and expertise and its partners in the field of antibacterials, which include screening and hit identification, structure-based drug design, and a broad platform for antibacterial drug discovery and antibiotic drug evaluation.